[{"id":"mace-hf","name":"Composite of CV death and heart failure events","type":"PRIMARY","results":[],"description":"Mortality and morbidity outcomes in HFpEF/HFmrEF with obesity. SELECT (semaglutide) showed 20% MACE reduction in obesity — sets the bar."}]

Enrolling ~5,000 patients. Long-duration outcomes trial. This is a label-expansion play for massive HFpEF market. Readout likely 2028+. Source: ClinicalTrials.gov NCT07037459

HFpEF patients with obesity have high unmet need. GLP-1 class has shown CV benefit (SELECT trial). Monthly dosing advantage in chronic disease.